Fagerstrom Test for Nicotine Dependence
How the Scales are Structured
Who Usually Takes This Test?
See How You Compare
Below is a preview of how scores are typically distributed across each scale.
Once you complete the test, your result will appear on the scale so you can see how you compare.
Frequently Asked Questions
/https://freudly.ai/media/tests/2074/image/1765325086_day_image_20251210_000445.png)
The Fagerstrom test for nicotine dependence is a 6-item self-report instrument that quantifies the severity of nicotine addiction based on two core behavioral indicators: time to first cigarette after waking and daily cigarette consumption, supplemented by four additional items assessing smoking patterns under restriction and compulsion. Scores range from 0 to 10 and classify dependence as low (0–3), moderate (4–6), or high (7–10), directly informing the intensity of smoking cessation support required.
Why Take the Fagerstrom Test for Nicotine Dependence
Not all smokers face the same quit challenge. A person with low nicotine dependence may succeed with behavioral support alone, while someone with high dependence is significantly more likely to need nicotine replacement therapy or pharmacological support to achieve smoking cessation. Knowing your dependence severity before attempting to quit helps match the right intervention to the right level of addiction from the start.
A Fagerstrom nicotine dependence assessment is used by clinicians, cessation counselors, and general practitioners to guide treatment planning and predict withdrawal symptoms intensity. For smokers, the result provides a concrete, validated number that cuts through the ambiguity of "I smoke but I could stop if I wanted to" — making it easier to have an honest conversation about tobacco addiction and what level of support is realistically needed.
What the Assessment Measures
- Time to first cigarette — the single strongest predictor of nicotine dependence severity; smoking within 5 minutes of waking indicates high physical addiction.
- Daily cigarette consumption — total number of cigarettes smoked per day, reflecting the overall volume of tobacco use and tolerance level.
- Difficulty refraining in restricted situations — inability to avoid smoking in no-smoking zones indicates strong compulsive tobacco addiction.
- Which cigarette would be hardest to give up — identifies whether the morning cigarette is the most important, a key marker of physical nicotine dependence.
- Smoking when ill — continuing to smoke even when sick enough to stay in bed indicates compulsive cigarette dependence that overrides self-care.
Who This Assessment Is For
The Fagerstrom test for nicotine dependence is appropriate for any adult who currently smokes and wants a clear, evidence-based picture of how physically dependent on nicotine they are. Smokers planning to quit use it to understand what level of support they are likely to need — behavioral coaching, nicotine replacement therapy, or prescription medication. Healthcare providers and cessation counselors use the FTND questionnaire during intake to calibrate treatment intensity and set realistic expectations about withdrawal symptoms. Family members of smokers also use it to better understand the physical basis of tobacco addiction and provide more informed support. The test takes 2 minutes and requires no clinical background — each item asks directly about smoking behavior.
Clinical Validity and Use in Practice
The Fagerstrom test for nicotine dependence was revised by Heatherton, Kozlowski, Frecker, and Fagerström and has become the most widely used brief measure of cigarette dependence in clinical and research settings globally. It demonstrates good internal consistency, acceptable test-retest reliability, and significant correlations with biochemical markers of nicotine exposure including cotinine levels. High FTND scores predict greater difficulty achieving smoking cessation, more severe withdrawal symptoms, and stronger response to pharmacological interventions including nicotine replacement therapy. Results should be interpreted alongside clinical context — the instrument is a screening tool, not a diagnostic classification — and repeated administration allows clinicians to track dependence shifts across a cessation program.